Volastra in-licenses Amgen’s KIF18A inhibitor sovilnesib

At present, sovilnesib is being evaluated in a Phase I trial to treat triple-negative breast cancer, platinum-resistant high-grade serous ovarian cancer. Credit: National Cancer Institute on Unsplash.